Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

876 - Target delineation and dose prescription for adaptive replanned intensity-modulated radiotherapy in nasopharyngeal carcinoma.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Xie Huan

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

X.D. Huan

Author affiliations

  • Radiation oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 876

Background

To investigate the feasibility and benefits of target re-delineation and dose prescription for adaptive replanned radiotherapy in nasopharyngeal carcinoma (NPC) patients who underwent intensity-modulated radiotherapy (IMRT).

Methods

Fifty-four consecutive NPC patients who underwent IMRT were enrolled in this study. The replanning CT (CT-II) for each patient was generated at the 22nd fraction of the IMRT. In Plan-I, GTVnx-I was defined as all detected gross disease. The high-risk clinical target volume (CTV1-I), as subclinical disease consisting of a 1-cm margin surrounding the GTVnx-I. The low-risk clinical target volume (CTV2), as a 0.5- to 1.0-cm margin surrounding the CTV1-I. In Plan-II, the GTVnx-II, as all detected gross disease detected after 22 fractions. CTV1-II maintained the extent of the originally irradiated CTV1-I, including the area in which the tumor disappeared/dissolved after 22 fractions. The CTV2 was not delineated. The doses prescribed were as follows: Plan-I: PGTVnx/rpn/nd 53-54 Gy/25 F; PCTV1/nd 47.5-48 Gy/25 F; PCTV2 45 Gy/25 F; and Plan-II: PGTVnx/rpn/nd: 15-15.5 Gy/7 F; PCTV1/nd 13.5 Gy/7 F. The parameters were compared. Clinical outcomes and toxicities were evaluated.

Results

The median reductions in the GTVnx, GTVnd-R, bilateral parotids and bilateral submandibular glands were 25.07%, 38.17%, 23.43% (left), 21.12% (right), 23.37% (left) and 23.00% (right) (P < 0.05), respectively; bilateral RPLN and GTVnd-L exhibited median reductions of 22.50% (left), 25.00% (right), and 32.80% (P > 0.05), respectively. The average V95% of PGTVnx reached nearly 100% in the two plans. Plan-II significantly reduced the Dmean% in the optic chiasma, thyroid gland, hypopharynx, spinal cord, brain stem, pituitary, oropharynx and oral cavity compared with Plan-A (P < 0.05). Recurrence did not occur in the regression area, and the acute reactions were mild. The 3-year OS/LRFFS/DMFS rates were 93.3%/90.5%/91.4%, respectively.

Conclusions

Adaptive replanned IMRT in NPC provided a new perspective for target re-delineation and dose prescription. The results of this study showed significant dosimetric and clinical benefits without recurrence and reducing survival.

Clinical trial identification

Legal entity responsible for the study

Sun Yat-sen University Cancer Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.